浏览全部资源
扫码关注微信
G250纳米抗体靶向的载药纳米微泡抑制肾癌细胞生长的实验研究
Inhibitory effect of G250 nanobody-targeted temsirolimus-loaded nanobubbles on growth of renal cancer cells
in vitro - 第三军医大学学报 2018年40卷第24期 页码：2229-2235
- 作者机构：
1.400042 重庆，陆军军医大学(第三军医大学)第三附属医院(野战外科研究所)泌尿外科
2.400038 重庆，陆军军医大学(第三军医大学)第一附属医院超声科
- 作者简介：
[王洛夫, E-mail：wangluofu@aliyun.com WANG Luofu, E-mail: wangluofu@aliyun.com
- 基金信息：国家自然科学基金面上项目(81472399)
DOI：10.16016/j.1000-5404.201807220
中图分类号： R73-36;R737.11;R944.9收稿：2018-07-31，
修回：2018-10-18，
纸质出版：2018-12-30
- 稿件说明：
移动端阅览
余志平, 胡明, 王洛夫, 等. G250纳米抗体靶向的载药纳米微泡抑制肾癌细胞生长的实验研究[J]. 第三军医大学学报, 2018,40(24):2229-2235.
Zhiping YU, Ming HU, Luofu WANG, et al. Inhibitory effect of G250 nanobody-targeted temsirolimus-loaded nanobubbles on growth of renal cancer cells
in vitro [J]. Journal of Third Military Medical University, 2018, 40(24): 2229-2235.余志平, 胡明, 王洛夫, 等. G250纳米抗体靶向的载药纳米微泡抑制肾癌细胞生长的实验研究[J]. 第三军医大学学报, 2018,40(24):2229-2235. DOI： 10.16016/j.1000-5404.201807220.
Zhiping YU, Ming HU, Luofu WANG, et al. Inhibitory effect of G250 nanobody-targeted temsirolimus-loaded nanobubbles on growth of renal cancer cells
in vitro [J]. Journal of Third Military Medical University, 2018, 40(24): 2229-2235. DOI： 10.16016/j.1000-5404.201807220.
摘要
目的
2
制备G250纳米抗体靶向的携载替西罗莫司的脂质纳米微泡(G250-TEM-NBs)，并联合超声靶向纳米微泡破坏(ultrasound targeted nano-bubble destruction
UTMD)辅助药物递送系统实现对肾癌细胞生长的抑制。
方法
2
采用水化薄膜法，联合机械震荡和静电作用制备G250-TEM-NBs，检测其粒径、ζ电位、包封率和载药效率。体外观察G250-TEM-NBs靶向结合肾癌786-O细胞的能力，通过CCK-8和TUNEL测量G250-TEM-NBs联合UTMD抗肿瘤细胞增殖诱导凋亡效果。
结果
2
G250-TEM-NBs平均粒径和ζ电位分别为(399.67±31.01)nm和(-23.33±2.62)mV，G250-TEM-NBs与肾癌786-O细胞的亲和力明显高于TEM-NBs(
P
＜0.05)，G250-TEM-NBs联合UTMD抗肿瘤细胞增殖能力及诱导肿瘤细胞凋亡作用最强。
结论
2
G250-TEM-NBs联合UTMD能显著抑制肾癌细胞生长，为肾癌靶向治疗提供了一种有效的新方法。
Abstract
Objective
2
To establish a drug delivery system based on G250 nanobody-targeted lipid nanobubbles carrying temsirolimus (G250-TEM-NBs) combined with ultrasound targeted nanobubble destruction (UTMD) and assess its inhibitory effect on the growth of renal cell carcinoma (RCC) cells
in vitro
.
Methods
2
G250-TEM-NBs were prepared using the hydration membrane method combined with mechanical vibration and electrostatic interaction
and the particle size
zeta potential
entrapment efficiency and drug loading efficiency were assessed. The binding ability of G250-TEM-NBs to renal cancer 786-O cells
in vitro
was evaluated
and CCK-8 and TUNEL assays were used to evaluate the growth inhibition and apoptosis-inducing effects of G250-TEM-NBs combined with UTMD in 786-O cells.
Results
2
The av
erage particle size and zeta potential of G250-TEM-NBs was 399.67±31.01 nm and -23.33±2.62 mV
respectively. The affinity of G250-TEM-NBs to 786-O cells was significantly higher than that of TEM-NBs (
P
<
0.05). When combined with UTMD
G250-TEM-NBs showed a strong inhibitory effect on the proliferation and potently induced apoptosis in 786-O cells.
Conclusion
2
G250-TEM-NBs combined with UTMD can significantly inhibit the growth of renal cancer cells
in vitro
which sheds light on a potentially effective new method for targeted therapy of RCC.
关键词
Keywords
references
LJUNGBERG B, BENSALAH K, CANFIELD S, et al . EAU guidelines on renal cell carcinoma: 2014 update[J ] . Eur Urol, 2015, 67(5): 913-924. DOI: 10.1016/j.eururo. 2015.01.005.
CAPITANIO U, MONTORSI F. Renal cancer[J]. Lancet, 2016, 387(10021): 894-906. DOI: 10.1016/S0140- 6736(15)00046-X.
KIM S W, KIM S J, PARK S H, et al . Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK[J ] . Clin Cancer Res, 2013, 19(2): 415-427. DOI: 10.1158/1078-0432.CCR-12- 1568.
JANG K W, SEOL D, DING L, et al . Ultrasound-triggered PLGA microparticle destruction and degradation for controlled delivery of local cytotoxicity and drug release[J ] . Int J Biol Macromol, 2018, 106: 1211-1217. DOI: 10.1016/j.ijbiomac.2017.08.125.
阳孟君, 王洛夫, 郭燕丽, 等.携载G250单克隆抗体的纳米微泡靶向于肾细胞癌的体内外实验研究[J].第三军医大学学报, 2016, 38(2): 112-118. DOI: 10.16016/j.1000-5404. 201508106.
YANG M J, WANG L F, GUO Y L, et al .In vivo and in vitro study of nanoscale microbubbles with G250 monoclonal antibodies targeting to renal cell carcinoma[J ] .J Third Mil Med Univ, 2016, 38(2): 112-118. DOI: 10.16016/j.1000- 5404. 201508106.
LIU L, YE Q, LU M, et al . A new approach to deliver anti-cancer nanodrugs with reduced off-target toxicities and improved efficiency by temporarily blunting the reticuloendothelial system with intralipid[J ] . Sci Rep, 2017, 7(1): 16106. DOI: 10. 1038/s41598-017-16293-6.
胡明, 王洛夫, 江军, 等.骆驼抗G250蛋白胞外区纳米抗体的制备及鉴定[J].第三军医大学学报, 2017, 39(6): 541-547. DOI: 10.16016/j.1000-5404. 201611198.
HU M, WANG L F, JIANG J, et al .Preparation and inentification of camel nanobodies against human G250 ectodomain[J ] .J Third Mil Med Univ, 2017, 39(06): 541-547. DOI: 10.16016/j.1000-5404.201611198.
SCHULZE M, STOCK C, ZACCAGNINI M, et al . Temsirolimus[J ] . Recent Results Cancer Res, 2014, 201: 393-403. DOI: 10.1007/978-3-642-54490-3_24.
BERGMANN L, MAUTE L, GUSCHMANN M. Temsirolimus for advanced renal cell carcinoma[J]. Expert Rev Anticancer Ther, 2014, 14(1): 9-21. DOI: 10.1586/ 14737140.2014.864562.
ZHAO H, WU M, ZHU L, et al . Cell-penetrating peptide-modified targeted drug-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound for precision theranostics against hepatocellular carcinoma[J ] . Theranostics, 2018, 8(7): 1892-1910. DOI: 10.7150/thno.22386.
LUO W, WEN G, YANG L, et al . Dual-targeted and pH-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment[J ] . Theranostics, 2017, 7(2): 452-465. DOI: 10.7150/thno.16677.
FAN X, WANG L, GUO Y, et al . Inhibition of prostate cancer growth using doxorubicin assisted by ultrasound-targeted nanobubble destruction[J ] . Int J Nanomedicine, 2016, 11: 3585-3596. DOI: 10.2147/IJN.S111808.
FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J ] . Int J Cancer, 2015, 136(5): E359-E386. DOI: 10.1002/ijc.29210.
RYAN C W. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma[J]. J Oncol Pharm Pract, 2017, 23(1): 43-55. DOI: 10.1177/ 1078155215618769.
PY A G, ZEIN ADDEEN G, PERRIER Y, et al . Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance[J ] . Ann Phys Rehabil Med, 2009, 52(3): 215-223. DOI: 10.1016/j.rehab.2009.02.005.
G VENER N, APPOLD L, DE LORENZI F, et al . Recent advances in ultrasound-based diagnosis and therapy with micro- and nanometer-sized formulations[J ] . Methods, 2017, 130: 4-13. DOI: 10.1016/j.ymeth.2017.05.018.
BOISSENOT T, BORDAT A, FATTAL E, et al . Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications[J ] . J Control Release, 2016, 241: 144-163. DOI: 10.1016/j.jconrel. 2016.09.026.
MOUSSA H G, MARTINS A M, HUSSEINI G A. Review on triggered liposomal drug delivery with a focus on ultrasound[J]. Curr Cancer Drug Targets, 2015, 15(4): 282-313. DOI: 10.2174/1568009615666150311100610.
P REZ-HERRERO E, FERN NDEZ-MEDARDE A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy[J]. Eur J Pharm Biopharm, 2015, 93: 52-79. DOI: 10.1016/j.ejpb.2015.03.018.
XING L, SHI Q, ZHENG K, et al . Ultrasound-mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nanoparticles in pancreatic cancer[J ] . Theranostics, 2016, 6(10): 1573-1587. DOI: 10.7150/thno.15164.
CAO Y, CHEN Y, YU T, et al . Drug release from phase-changeable nanodroplets triggered by low-intensity focused ultrasound[J ] . Theranostics, 2018, 8(5): 1327-1339. DOI: 10.7150/thno.21492.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
